Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Maximilian Vidovic
Observed name:
Vidovic, Maximilian
Institutions:
University Hospital Carl Gustav Carus,
Technische Universität Dresden
Observed institutions:
University Hospital Carl Gustav Carus,
Technische Universität Dresden
ORCID:
0000-0003-1453-1681
Observed ORCID:
0000-0003-1453-1681
OpenAlex ID:
A5004331057
Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access program
2024
·
Maximilian Wiesenfarth
, Johannes Dorst
, et al.
·
EClinicalMedicine
·
129
PDF
Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1 ‐related ALS : Treatment experience in clinical practice
2023
·
Thomas Meyer
, Peggy Schumann
, et al.
·
Muscle & Nerve
·
107
PDF
Current State and Future Directions in the Diagnosis of Amyotrophic Lateral Sclerosis
2023
·
Maximilian Vidovic
, Lars Hendrik Müschen
, et al.
·
Cells
·
91
PDF
Clinical and patient‐reported outcomes and neurofilament response during tofersen treatment in SOD1 ‐related ALS —A multicenter observational study over 18 months
2024
·
Thomas Meyer
, Peggy Schumann
, et al.
·
Muscle & Nerve
·
42
PDF
Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis: A longitudinal, multicenter study
2024
·
Thomas Meyer
, Marie Dreger
, et al.
·
European Journal of Neurology
·
40
PDF
Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis
2025
·
Christina Steffke
, Karthik Baskar
, et al.
·
Annals of Neurology
·
18
PDF
Comparative analysis of neurofilaments and biomarkers of muscular damage in amyotrophic lateral sclerosis
2024
·
Maximilian Vidovic
, Hanna Sophie Lapp
, et al.
·
Brain Communications
·
16
PDF
A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial
2023
·
Flavia L. Lombardo
, Stefania Spila Alegiani
, et al.
·
Trials
·
16
PDF
SOD1 gene screening in ALS – frequency of mutations, patients’ attitudes to genetic information and transition to tofersen treatment in a multi-center program
2024
·
Thomas Meyer
, Peggy Schumann
, et al.
·
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
·
12
PDF
Self-assessment of amyotrophic lateral sclerosis functional rating scale on the patient’s smartphone proves to be non-inferior to clinic data capture
2025
·
Laura Steinfurth
, Torsten Grehl
, et al.
·
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
·
10
Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen
2023
·
Maximilian Vidovic
, Maren Freigang
, et al.
·
BMC Neurology
·
10
PDF
Macrophage inclusions in cerebrospinal fluid following treatment initiation with antisense oligonucleotide therapies in motor neuron diseases
2024
·
Maximilian Vidovic
, Mario Menschikowski
, et al.
·
Neurological Research and Practice
·
8
PDF
Patients’ and caregivers’ perception of multidimensional and palliative care in amyotrophic lateral sclerosis – protocol of a German multicentre study
2024
·
Katharina Linse
, Constanze Weber
, et al.
·
Neurological Research and Practice
·
7
PDF
Between guidelines and reality: expert neurologists’ perspectives on structural resources for ALS care in Germany
2026
·
Katharina Linse
, Dorothée Lulé
, et al.
·
Neurological Research and Practice
·
4
PDF
The palmomental reflex in amyotrophic lateral sclerosis – a clinical sign of executive or motor dysfunction?
2021
·
Maximilian Vidovic
, Elisa Aust
, et al.
·
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
·
3
Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2026
·
Merit E Cudkowicz
, Jeremy Shefner
, et al.
·
The Lancet Neurology
·
2
Methotrexate therapy as a promising long-term treatment approach for immune-mediated adverse reactions of tofersen in SOD1-ALS: a case report
2025
·
Maximilian Vidovic
, Hanna Sophie Lapp
, et al.
·
Journal of Neurology
·
1
PDF
Correction: Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen
2023
·
Maximilian Vidovic
, Maren Freigang
, et al.
·
BMC Neurology
PDF
Show more works
View as search
Works count:
21
Citation count:
516
H-index:
10
I10-index:
11
Year
Topic
Type